Clinical Trial Update: Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML). [Phase 1]

View source ↗

Summary

Phase 1 study evaluating alvocidib with cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Alvocidib (Flavopiridol)
• CYTARABINE (CYTARABINE)
• Daunorubicin (daunorubicin)

Snippet

Sponsor: Sumitomo Pharma America, Inc. | Conditions: Acute Myeloid Leukemia | Phase 1 | Status: COMPLETED | Results posted: 2021-05-24